Liberation Bioindustries Closes Series A1 to Advance 600,000-Liter Precision Fermentation Facility
Liberation Bioindustries, formerly known as Liberation Labs, has reached a major milestone with the first close of its Series A1 equity funding round as the company advances construction of its first 600,000‑liter precision fermentation facility in Richmond, Indiana. The fundraising reflects growing investor confidence in the company’s infrastructure‑first approach to serving the expanding market for bio‑based ingredients and materials.
The Series A1 round includes a significant equity conversion by Agronomics Limited, a London-listed investment firm focused on cellular agriculture and alternative proteins. Agronomics converted its existing convertible loan notes into Series A1 shares, increasing its holding and underscoring its long-term commitment to Liberation Bioindustries’ growth strategy. An affiliate of Agronomics, New Agrarian Company Limited, also committed capital to the round, further strengthening the funding base for the company’s biomanufacturing expansion.
To date, Agronomics has invested a total of approximately US$27 million in Liberation Bioindustries, a figure now carried at roughly US$46.8 million after the conversion of convertible notes into equity. This shift from debt to equity at a higher valuation reflects investor confidence in the company’s construction milestones and commercialization path as it advances toward production.
Liberation Bioindustries, which rebranded from Liberation Labs in mid‑2025 to better reflect its industrial-scale ambitions, is building a purpose-built precision fermentation facility designed to produce a wide range of bio-based materials, including proteins and other ingredient building blocks for food and industrial applications. The Richmond facility will support commercial volumes that meet demand from consumer packaged goods companies and industrial manufacturers seeking reliable and scalable domestic biomanufacturing capacity.
The push into full commercial operations comes amid strategic partnerships that highlight an expanding footprint for Liberation Bioindustries. In 2025, the company announced plans to produce Vivitein™ BLG, a dairy protein developed by Dutch startup Vivici, at commercial scale in its Richmond facility once operational. Earlier in 2025, Liberation announced a partnership with Topian, NEOM’s food company, to collaborate on a precision fermentation facility in Saudi Arabia, signaling global interest and opportunities for the company’s manufacturing platform.
The capital raised in the Series A1 round will accelerate the completion of the Richmond plant, a critical piece of infrastructure for the growing precision fermentation sector. The facility aims to fill a longstanding gap in domestic biomanufacturing capacity, enabling biotech innovators to scale production cost-effectively and reliably without relying on complex overseas supply chains.
The momentum behind Liberation Bioindustries’ funding builds on prior financings and capital formation efforts. In early 2025, as Liberation Labs, the company closed a $50.5 million convertible note round that supported construction progress on the Richmond facility and brought total deployable capital, including public sector awards and loan guarantees, to more than US$125 million. That earlier financing featured participation from investors including NEOM Investment Fund, Galloway Limited, Meach Cove Capital, and existing backers such as Agronomics, New Agrarian Capital, and Siddhi Capital, demonstrating broad backing for the company’s mission to expand precision fermentation capacity.
Liberation Bioindustries’ vision is to be a contract manufacturer that bridges the gap between lab-scale biotech innovation and commercial production at scale. By offering dedicated infrastructure and downstream capabilities, the company positions itself as an essential partner for brands and innovators looking to bring bio-based products to market efficiently.
As construction nears completion, the company is poised to begin operations that could have a meaningful impact on the domestic bioeconomy, supporting growing demand for sustainable, precision-manufactured ingredients across sectors such as food, pharmaceuticals, specialty chemicals, and industrial materials. The successful Series A1 equity close and strong investor participation signal confidence that Liberation Bioindustries is on track to deliver its first commercial-scale biomanufacturing output in the near term.
